Home » Stocks » Gritstone Oncology

Gritstone Oncology, Inc. (GRTS)

Stock Price: $6.58 USD 0.03 (0.46%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 245.20M
Revenue (ttm) 4.28M
Net Income (ttm) -102.63M
Shares Out 37.27M
EPS (ttm) -2.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $6.58
Previous Close $6.55
Change ($) 0.03
Change (%) 0.46%
Day's Open 6.66
Day's Range 6.51 - 6.69
Day's Volume 227,039
52-Week Range 5.42 - 12.96

More Stats

Market Cap 245.20M
Enterprise Value 159.85M
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 37.27M
Float 16.74M
EPS (basic) -2.88
EPS (diluted) -2.89
FCF / Share -2.83
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.45M
Short Ratio 13.99
Short % of Float 14.29%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 57.29
PB Ratio 2.12
Revenue 4.28M
Operating Income -105.68M
Net Income -102.63M
Free Cash Flow -104.07M
Net Cash 85.36M
Net Cash / Share 2.29
Gross Margin -1,834.84%
Operating Margin -2,469.21%
Profit Margin -2,397.90%
FCF Margin -2,431.43%
ROA -39.03%
ROE -82.90%
ROIC -90.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 4
Overweight 2
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$20.83*
(216.57% upside)
Low
16.0
Current: 6.58
High
31.0
Target: 20.83
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue4.371.19--
Revenue Growth267.73%---
Gross Profit4.371.19--
Operating Income-97.94-65.58-41.76-18.98
Net Income-94.43-64.78-41.38-18.75
Shares Outstanding33.558.922.001.67
Earnings Per Share-2.81-7.26-20.70-11.21
Operating Cash Flow-85.01-38.16-34.97-15.29
Capital Expenditures-16.17-5.66-11.49-6.98
Free Cash Flow-101-43.83-46.46-22.28
Cash & Equivalents12815385.9537.51
Total Debt23.4910.4910.52-
Net Cash / Debt10414375.4337.51
Assets18419011746.42
Liabilities50.0540.4420.024.73
Book Value13414997.2841.69
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Gritstone Oncology, Inc.
Country United States
Employees 176
CEO Andrew R. Allen

Stock Information

Ticker Symbol GRTS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GRTS
IPO Date September 28, 2018

Description

Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.